1. France Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Eurofins-Cerep SA

Eurofins-Cerep SA

EEURONEXT:ALECR
18,400.00
EUR
+300.00
(+1.66%)
86.76MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,978.92
3,669.78
4,463.6
4,646.71
5,158.49
5,046.25
6,147.55
6,476.44
8,250.75
9,442.59
8,737
8,020.87
8,123.52
- -
Basic EPS, GAAP
-175.01
-98.16
358.53
492.86
813.61
764.98
866.43
1,105.73
1,951.38
2,284.78
1,514.43
1,418.43
948.15
- -
Free Cash Flow per Basic Share
-437.03
-700.66
-102.56
5.55
671.17
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2,707.33
2,610.76
2,967.74
3,460.94
4,224.15
4,989.05
5,855.4
6,961.05
8,995.88
11,286.65
12,810.2
14,222.85
15,163.19
16,112.81
Tangible Book Value per Share
2,692.1
2,593.73
2,964.99
3,407.41
4,171.13
4,936.23
5,406.55
6,518.17
8,552.99
10,843.76
12,367.31
13,739.93
14,705.05
15,644.92
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
20
18
23
23
24
25
31
33
42
48
44
40
41
- -
Operating Margin (%)
0.02
29.32
4.38
6.96
15.54
19.17
14.12
17.78
24.27
24.61
14.63
10.96
8.75
- -
Depreciation Expense
1
- -
1
-1
- -
1
1
1
1
2
2
2
2
- -
Net Income, GAAP
-1
- -
2
2
4
4
4
6
10
12
8
7
5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4.4
-2.67
8.03
10.61
15.77
15.16
14.09
17.07
23.65
24.2
17.33
17.68
11.67
- -
Working Capital
15
14
15
15
19
22
24
29
36
46
53
62
69
74
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
14
13
15
17
21
25
30
35
45
57
65
72
76
81
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-6.44
-3.69
12.86
15.33
19.86
16.61
15.98
17.25
24.46
22.53
12.57
10.49
6.45
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
104
90
87

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
74
79
83
Cash, Cash Equivalents & STI
14
21
19
Accounts Receivable, Net
8
8
8
Inventories
3
3
3
Total Current Liabilities
9
10
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.89%
17.17%
6.61%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
15.38%
4.07%
-33.15%
Sales/Revenue/Turnover
6.72%
5.49%
1.28%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
40
2025
- -
- -
41
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,418.43
2025
- -
- -
948.15
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Damien Vielliard
Full Time Employees
209
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Le Bois l'Evêque Celle l'Evescault France 86600
IPO Date
Mar 19, 2010
Website
eurofins.fr
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Eurofins-Cerep SA provides drug discovery services, including compound management, high-throughput screening, profiling, in vitro pharmacology, in vitro ADME-Tox studies, and in vivo pharmacokinetic services, to pharmaceutical, biopharmaceutical, and biotechnology companies in France and internationally. Founded in 1989 and headquartered in Celle-Lévescault, France, the company operates as a subsidiary of Eurofins Discovery Services LUX Holding SARL, following its name change from Cerep SA in June 2014. Eurofins-Cerep specializes in pre-clinical research solutions for drug development, with exports accounting for the majority of its net sales.